S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,163.92 (-1.89%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,453.61 (-2.41%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,163.92 (-1.89%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,453.61 (-2.41%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,163.92 (-1.89%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,453.61 (-2.41%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,163.92 (-1.89%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,453.61 (-2.41%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NASDAQ:CBIOCatalyst Biosciences Stock Price, Forecast & News

$5.39
+0.02 (+0.37 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.30
Now: $5.39
$5.51
50-Day Range
$5.11
MA: $5.84
$7.27
52-Week Range
$3.43
Now: $5.39
$8.94
Volume152,684 shs
Average Volume300,188 shs
Market Capitalization$65.10 million
P/E RatioN/A
Dividend YieldN/A
Beta2.32
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.
Read More
Catalyst Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CBIO
CUSIP87611R30
Phone650-871-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Book Value$5.68 per share

Profitability

Net Income$-55,180,000.00

Miscellaneous

Employees21
Market Cap$65.10 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$5.39
+0.02 (+0.37 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

How has Catalyst Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Catalyst Biosciences' stock was trading at $4.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CBIO shares have increased by 11.6% and is now trading at $5.39.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Catalyst Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Catalyst Biosciences
.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Catalyst Biosciences
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences Inc (NASDAQ:CBIO) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by $0.10.
View Catalyst Biosciences' earnings history
.

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Shares of Catalyst Biosciences reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CBIO?

3 brokers have issued 1 year price objectives for Catalyst Biosciences' stock. Their forecasts range from $18.00 to $25.00. On average, they expect Catalyst Biosciences' share price to reach $21.00 in the next year. This suggests a possible upside of 289.6% from the stock's current price.
View analysts' price targets for Catalyst Biosciences
.

Has Catalyst Biosciences been receiving favorable news coverage?

News headlines about CBIO stock have been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Catalyst Biosciences earned a coverage optimism score of 2.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Catalyst Biosciences
.

Who are some of Catalyst Biosciences' key competitors?

What other stocks do shareholders of Catalyst Biosciences own?

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the following people:
  • Dr. Nassim Usman, Pres, CEO & Director (Age 59)
  • Mr. Fletcher Payne, Chief Financial Officer (Age 56)
  • Dr. Howard Levy, Chief Medical Officer (Age 65)
  • Dr. Charles S. Craik, Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include UBS Group AG (1.33%), Assenagon Asset Management S.A. (1.25%), Trexquant Investment LP (0.45%), Raymond James Financial Services Advisors Inc. (0.35%), New York State Common Retirement Fund (0.13%) and Marquette Asset Management LLC (0.05%). Company insiders that own Catalyst Biosciences stock include Eddie Williams, Howard Levy, John P Richard, Nassim Usman and Veronica Cai.
View institutional ownership trends for Catalyst Biosciences
.

Which institutional investors are selling Catalyst Biosciences stock?

CBIO stock was sold by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC.
View insider buying and selling activity for Catalyst Biosciences
.

Which institutional investors are buying Catalyst Biosciences stock?

CBIO stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Assenagon Asset Management S.A., Trexquant Investment LP, Raymond James Financial Services Advisors Inc., and New York State Common Retirement Fund. Company insiders that have bought Catalyst Biosciences stock in the last two years include Eddie Williams, Howard Levy, John P Richard, Nassim Usman, and Veronica Cai.
View insider buying and selling activity for Catalyst Biosciences
.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $5.39.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $65.10 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($4.60) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe.

What is Catalyst Biosciences' official website?

The official website for Catalyst Biosciences is www.catalystbiosciences.com.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.